Stocks · News reference
Recursion Commences $200M Common Stock Offering Of 61,540,000 Shares Of Its Class A Common Stock At A Price Of $3.25/Share
Recursion (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today announced a $200 million underwritten offering of common
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Recursion Pharmaceuticals shares are trading after Needham reiterated its Buy rating on the stock and maintained a $8 price target.
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target
Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $8 price target.
Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know
Recursion Pharmaceuticals shares rise 0.24% after hours following a $200 million stock offering and a $10 million Sanofi milestone payment.